Adebayo Fasanya, MD
Pulmonary Disease · Fort Smith, ARNPI 1508111212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 477 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,735, 3.1 times the $554 reported in 2019.
Across 477 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$761
- Regeneron Healthcare Solutions, Inc.$676
- Philips North America LLC$401
- Mylan Specialty L.p.$363
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$1001%
- Food & beverage$8,04496%
- Education$2203%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 101 | $1,699 |
| GSK | 123 | $1,691 |
| Boehringer Ingelheim | 39 | $761 |
| Regeneron Healthcare Solutions, Inc. | 32 | $676 |
| Philips North America LLC | 23 | $401 |
| Mylan Specialty L.p. | 17 | $363 |
| Sanofi | 16 | $337 |
| Actelion Pharmaceuticals US, Inc. | 12 | $268 |
| Genentech USA, Inc. | 10 | $243 |
| United Therapeutics Corporation | 11 | $241 |
| Viatris Specialty LLC | 13 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $193 |
| Gilead | 9 | $161 |
| Harmony Biosciences LLC | 8 | $128 |
| Jazz Pharmaceuticals Inc. | 6 | $118 |
| Merck | 5 | $85 |
| Verona Pharma, Inc. | 4 | $81 |
| Amgen | 4 | $79 |
| Advanced Respiratory, Inc | 3 | $68 |
| Grifols USA, LLC | 3 | $65 |
| Mallinckrodt Hospital Products Inc. | 3 | $58 |
| Insmed, Inc. | 3 | $54 |
| Pfizer | 3 | $47 |
| ANI Pharmaceuticals, Inc. | 3 | $46 |
| Inari Medical, Inc. | 2 | $39 |
| Johnson & Johnson(2 entities) | 2 | $37 |
| Baxter Healthcare | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Electromed, Inc. | 2 | $23 |
| Ambu Inc. | 1 | $22 |
| Olympus America Inc. | 1 | $19 |
| Abiomed | 1 | $15 |
| G1 Therapeutics, Inc. | 1 | $13 |
| Chiesi USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$250
- AREXVY$125
- Yupelri$125
How this compares
$8,364 in reported general payments places this provider in the 75th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 325 | $232,631 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $66,207 |
| Spiriva HandihalerTiotropium Bromide | 47 | $29,540 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $28,534 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $17,203 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $17,054 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 273 | $8,236 |
| Ventolin HfaAlbuterol Sulfate | 112 | $7,370 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $6,748 |
| Varenicline Tartrate | 36 | $6,079 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $3,962 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $2,924 |
| Montelukast Sodium | 119 | $590 |
| Fluticasone Propionate | 55 | $546 |
| Prednisone | 127 | $436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,691 | $344,426530 claims |
| AstraZenecaSymbicort | $1,699 | $17,20359 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Fort Smith
- Arturo MeadeFort Smith$67K
- Daphne MacbruceFort Smith$10K
- Muhammad MirFort Smith$4K
- Sarikun TjandraFort Smith$3K
- Francisco TamayoFort Smith$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.